Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study.

Pontiroli AE, Pajetta E, Scaglia L, Rubinacci A, Resmini G, Arrigoni M, Pozza G

Aging (Milan, Italy)1 Dec 1994Cited by 14 (Europe PMC)

PMID7748920DOI10.1007/bf03324278PepBankPUB-07748920

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with painful postmenopausal osteoporosis, final pain scores did not differ between intranasal salmon calcitonin and placebo.
In plain wordsIn women with painful postmenopausal osteoporosis, final pain scores did not differ between intranasal salmon calcitonin and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeFinal pain score, intranasal versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Pain · Musculoskeletal
Studied dose
200 U/day · intranasal · 4 weeksAs given in this study (human).
Source sentences
Summary
so that the final pain scores obtained with the three treatments were not different.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the analgesic efficacy of i.n. and intramuscular (i.m.) salmon calcitonin (sCT) and of placebo in women affected by painful post-menopausal osteoporosis, in a double-blind, double-placebo trial.
Summary · context
Twenty-eight women were randomly allocated to one of the following treatments: 1) i.n. sCT 200 U/day plus i.m. placebo; 2) i.n. placebo plus i.m. sCT 100 U/day; and 3) i.n. and i.m. placebo.
Summary · context
Each treatment lasted four weeks, and the pain score was evaluated weekly by means of a visual analogic scale (VAS).
Report a problemFND-0774892003
02HumanRandomized controlled trialEfficacy outcome
In women with painful postmenopausal osteoporosis, final pain scores did not differ between intramuscular salmon calcitonin and placebo.
In plain wordsIn women with painful postmenopausal osteoporosis, final pain scores did not differ between intramuscular salmon calcitonin and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeFinal pain score, intramuscular versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Pain · Musculoskeletal
Studied dose
100 U/day · intramuscular · 4 weeksAs given in this study (human).
Source sentences
Summary
so that the final pain scores obtained with the three treatments were not different.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the analgesic efficacy of i.n. and intramuscular (i.m.) salmon calcitonin (sCT) and of placebo in women affected by painful post-menopausal osteoporosis, in a double-blind, double-placebo trial.
Summary · context
Twenty-eight women were randomly allocated to one of the following treatments: 1) i.n. sCT 200 U/day plus i.m. placebo; 2) i.n. placebo plus i.m. sCT 100 U/day; and 3) i.n. and i.m. placebo.
Summary · context
Each treatment lasted four weeks, and the pain score was evaluated weekly by means of a visual analogic scale (VAS).
Report a problemFND-0774892004
03HumanRandomized controlled trialEfficacy outcome
In women with painful postmenopausal osteoporosis, final pain scores did not differ between intranasal and intramuscular salmon calcitonin.
In plain wordsIn women with painful postmenopausal osteoporosis, final pain scores did not differ between intranasal and intramuscular salmon calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeFinal pain score, intranasal versus intramuscular
Study
n: not reported in source
Comparator
Intramuscular salmon calcitonin 100 U/day
Outcome group
Pain · Musculoskeletal
Studied dose
200 U/day · intranasal · 4 weeksAs given in this study (human).
Source sentences
Summary
so that the final pain scores obtained with the three treatments were not different.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the analgesic efficacy of i.n. and intramuscular (i.m.) salmon calcitonin (sCT) and of placebo in women affected by painful post-menopausal osteoporosis, in a double-blind, double-placebo trial.
Summary · context
Twenty-eight women were randomly allocated to one of the following treatments: 1) i.n. sCT 200 U/day plus i.m. placebo; 2) i.n. placebo plus i.m. sCT 100 U/day; and 3) i.n. and i.m. placebo.
Summary · context
Each treatment lasted four weeks, and the pain score was evaluated weekly by means of a visual analogic scale (VAS).
Report a problemFND-0774892005
04HumanNon-randomized trialEfficacy outcome
In women with painful postmenopausal osteoporosis, intranasal salmon calcitonin significantly reduced pain scores by the second week.
In plain wordsIn women with painful postmenopausal osteoporosis, intranasal salmon calcitonin reduced pain from baseline by the second week.
Peptide
Calcitonin-salmon
Outcome
DecreasePain score by second week
Study
n: not reported in source
Outcome group
Pain · Musculoskeletal
Studied dose
200 U/day · intranasal · 4 weeksAs given in this study (human).
Source sentences
Summary
with i.n. sCT, the pain score decreased significantly by the second week of treatment (p < 0.05)
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the analgesic efficacy of i.n. and intramuscular (i.m.) salmon calcitonin (sCT) and of placebo in women affected by painful post-menopausal osteoporosis, in a double-blind, double-placebo trial.
Summary · context
Twenty-eight women were randomly allocated to one of the following treatments: 1) i.n. sCT 200 U/day plus i.m. placebo; 2) i.n. placebo plus i.m. sCT 100 U/day; and 3) i.n. and i.m. placebo.
Summary · context
Each treatment lasted four weeks, and the pain score was evaluated weekly by means of a visual analogic scale (VAS).
Report a problemFND-0774892001
05HumanNon-randomized trialEfficacy outcome
In women with painful postmenopausal osteoporosis, pain scores decreased significantly only by the fourth week with intramuscular salmon calcitonin, as they also did with placebo.
In plain wordsIn women with painful postmenopausal osteoporosis, pain scores fell only by the fourth week with intramuscular salmon calcitonin, and also with placebo.
Peptide
Calcitonin-salmon
Outcome
DecreasePain score by fourth week
Study
n: not reported in source
Outcome group
Pain · Musculoskeletal
Studied dose
100 U/day · intramuscular · 4 weeksAs given in this study (human).
Source sentences
Summary
with i.m. sCT and with placebo, the pain score decreased significantly only by the fourth week (p < 0.05)
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the analgesic efficacy of i.n. and intramuscular (i.m.) salmon calcitonin (sCT) and of placebo in women affected by painful post-menopausal osteoporosis, in a double-blind, double-placebo trial.
Summary · context
Twenty-eight women were randomly allocated to one of the following treatments: 1) i.n. sCT 200 U/day plus i.m. placebo; 2) i.n. placebo plus i.m. sCT 100 U/day; and 3) i.n. and i.m. placebo.
Summary · context
Each treatment lasted four weeks, and the pain score was evaluated weekly by means of a visual analogic scale (VAS).
Report a problemFND-0774892002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.